📰 Overall Response News
Overall Response News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Overall Response. Real-time updates on events, politics, business and more.
May 23, 2024
/PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics,...
October 24, 2023
Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer...
October 18, 2023
– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR –
June 5, 2023
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
May 2, 2023
Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203
April 17, 2023
CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.
January 8, 2022
PD-1 and PD-L1 Evolution, Navigating through Lines of Therapy; Market Outlook, Competitive Landscape, Drug Utilization, and Market Forecast by cancer Types
January 8, 2022
PD-1 and PD-L1 Evolution, Navigating through Lines of Therapy; Market Outlook, Competitive Landscape, Drug Utilization, and Market Forecast by cancer Types
December 14, 2021
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
December 12, 2021
Epizyme, Inc. , a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and... | December 12, 2021